Progress and challenges in obesity pharmacotherapy: semaglutide as a milestone.
肥胖藥物治療的進展與挑戰:semaglutide 作為一個里程碑
Naunyn Schmiedebergs Arch Pharmacol 2025-06-14
Intranasal Absorption Enhancement of Antidiabetic Therapeuticals by the Functional Peptide Segment of Latroeggtoxin-VI.
Latroeggtoxin-VI 功能性胜肽片段增強抗糖尿病治療藥物之鼻腔吸收
Mol Pharm 2025-06-14
Interleukin-1β in circulating mononuclear cells predicts steatotic liver disease improvement after weight loss in subjects with obesity and prediabetes or type 2 diabetes.
循環單核細胞中的 Interleukin-1β 可預測肥胖且有前期糖尿病或第二型糖尿病患者在減重後脂肪肝疾病的改善
Cardiovasc Diabetol 2025-06-13
[Bariatric surgery versus GLP-1 and dual GIP/GLP-1 receptor agonists : Effects on weight, risk factors and prognosis].
減重手術與GLP-1及雙重GIP/GLP-1受體促效劑之比較:對體重、危險因子及預後的影響
Herz 2025-06-13
Designing structure-specific and switchable allosteric effectors for GPCRs based on the causality and energetics of inherent signaling.
基於內在訊號傳導的因果關係與能量學,設計結構特異性且可切換的GPCRs變構效應劑
J Mol Biol 2025-06-13